Concepedia

Publication | Open Access

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

DOIFull Paper Access

1.7K

Citations

15

References

2021

Year

Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal,
New England Journal of Medicine

Abstract

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).

References

YearCitations

Page 1